CLAIMS

1. A composition comprising about 75 mg of vibegron for use in treating overactive bladder in a treatment-experienced subject in need thereof, wherein following administration of the composition to the subject over a treatment period:
   a. the decrease in the average number of micturitions in a 24-hour period in the subject is about 1.5 to about 10 more than the decrease in the average number of micturitions in a subject who receives a placebo; or
   b. the average number of urge urinary incontinence (UUI) episodes per 24 hours by the subject decreases by about 1.7 to about 6 times the decrease as that of a subject treated with placebo.

2. The composition of claim 1, wherein the decrease in the average number of micturitions in a 24-hour period in the subject is about 2 to about 4 more than the decrease in the average number of micturitions in a subject who receives a placebo.

3. The composition of claim 1 or 2, wherein following administration of the composition to the subject over a treatment period the average number of micturitions per 24 hours by the subject decreases from about -1.3 to about -2.5 and the average number of UUI episodes per 24 hours by the subject decreases from about -1.5 to about -2.5.

4. The composition of any one of claims 1-3, wherein following administration of the composition to the subject over a treatment period the average number of micturitions in a 24-hour period by the subject decreases between about 1.5 and about 10 compared to the average number of micturitions in a subject who receives a placebo and the average number of UUI episodes per 24 hours by the subject decreases from about -1.5 to about -2.5.

5. The composition of any one of claims 1 to 4, wherein following administration of the composition to the subject over a treatment period the average number of urgency episodes per 24 hours decreases by about -2.2 to about -3.5.

6. The composition of any one of claims 1 to 5, wherein following administration of the composition to the subject over a treatment period the average number of total incontinence episodes decreases by about -1.7 to about -2.7.

7. The composition of any one of claims 1 to 6, wherein following administration of the composition to the subject over a treatment period the average amount of volume voided per micturition increases by about 18 mL to about 30 mL.

8. The composition of any one of claims 1-7, wherein the treatment-experienced subject has been previously treated with an anticholinergic.

9. The composition of claim 8, wherein the treatment-experienced subject has been treated with an anticholinergic within 12 months prior to treatment with vibegron.

10. The composition of claim 8, wherein the treatment-experienced subject has been treated with an anticholinergic more than 12 months prior to treatment with vibegron.

11. The composition of claim 8, wherein the treatment-experienced subject is concomitantly receiving an anticholinergic.

12. The composition of any one of claims 1-8, wherein the treatment-experienced subject has been previously treated with a beta-3 agonist other than vibegron.

13. The composition of claim 12, wherein the beta-3 agonist is mirabegron.

14. The composition of claim 12 or 13, wherein the treatment-experienced subject has been treated with a beta-3 agonist other than vibegron within 12 months prior to treatment with vibegron.

15. The composition of claim 12 or 13, wherein the treatment-experienced subject has been treated with a beta-3 agonist other than vibegron more than 12 months prior to treatment with vibegron.

16. The composition of claim 12 or 13, wherein the treatment-experienced subject is concomitantly receiving a beta-3 agonist other than vibegron.

17. A composition comprising about 75 mg of vibegron for use in treating overactive bladder in a subject in need thereof while improving Health-related Quality of Life (HRQL) , wherein the improvement is compared to the HRQL of a subject receiving placebo.

18. The composition of claim 17, wherein the HRQL includes one or more subscales selected from coping, concern, sleep, or social interaction.

19. The composition of claim 17 or 18, wherein the improvement in HRQL is greater than with tolterodine extended release (ER) 4mg.

20. The composition of any one of claims 17 to 19, wherein the HRQL of the subject receiving vibegron is improved by a total score of at least about 3.8 compared to a subject receiving placebo.

21. A composition comprising about 75 mg of vibegron for use in reducing coping behaviors in a subject suffering from overactive bladder symptoms, wherein the coping behaviors in the subject are reduced compared to a subject receiving placebo.

22. A comprising about 75 mg of vibegron for use in improving coping domain score in a subject suffering from overactive bladder symptoms, wherein the improvement is compared to the coping domain score of a subject receiving placebo.

23. The composition of claim 22, wherein the improvement in coping domain score is greater than with tolterodine extended release (ER) 4mg.

24. The composition of claim 22 or 23, wherein the coping domain score of the subject receiving vibegron is improved by a score of at least about 3.2 compared to a subject receiving placebo.

25. A composition comprising about 75 mg of vibegron for use in improving sleep in a subject suffering from overactive bladder symptoms, wherein the improvement is compared to the sleep of a subject receiving placebo.

26. The composition of claim 25, wherein the improvement in sleep is greater than with tolterodine extended release (ER) 4mg.

27. The composition of claim 25 or 26, wherein the sleep of the subject receiving vibegron is improved compared to a subject receiving placebo by a score of at least about 2.6.

28. A composition comprising about 75 mg of vibegron for use in decreasing symptom bother in a subject suffering from overactive bladder symptoms, wherein the decrease is compared to the symptom bother of a subject receiving placebo.

29. The composition of claim 28, wherein the decrease in symptom bother is greater than with tolterodine extended release (ER) 4mg.

30. The composition of claim 28 or 29, wherein the symptom bother of the subject receiving vibegron is decreased compared to a subject receiving placebo by a score of at least about -5.0.

31. A composition comprising about 75 mg of vibegron for use in maintaining daytime ambulatory blood pressure while treating overactive bladder in a subject in need thereof, wherein the subject experiences a mean change of daytime ambulatory blood pressure over a treatment period of less than about 2.0 mm Hg.

32. The composition of claim 31, wherein the subject experiences a mean change of daytime ambulatory systolic blood pressure over a treatment period and wherein the mean change from that of a subject taking a placebo has an upper bound of a 90% confidence interval less than about 3.5 mm Hg.

33. The composition of claim 32, wherein the upper bound of a 90% confidence interval is less than about 2.5 mm Hg.

34. The composition of claim 33, wherein the upper bound of a 90% confidence interval is about 2.0 mm Hg.

35. The composition of any one of claims 31 to 34, wherein the subject experiences a mean change of daytime ambulatory systolic blood pressure over a treatment period and wherein the mean change is less than about 1.0 mm Hg from that of a subject taking a placebo.

36. The composition of claim 35, wherein the mean change is less than about 0.5 mm Hg from that of a subject taking a placebo.

37. The composition of any one of claims 31 to 36, wherein the subject experiences a mean change of daytime ambulatory systolic blood pressure over a treatment period of less than about 1.0 mm Hg.

38. The composition of claim 37, wherein the mean change is less than about 0.25 mm Hg.

39. The composition of any one of claims 31 to 38, wherein the subject does not experience a mean change of daytime ambulatory diastolic blood pressure over a treatment period greater than that of a subject taking a placebo.

40. The composition of any one of claims 31 to 39, wherein the subject experiences a mean change of daytime ambulatory diastolic blood pressure over a treatment period of less than about 0.75 mm Hg.

41. A composition comprising about 75 mg of vibegron for use in maintaining daytime ambulatory heart rate while treating overactive bladder in a subject in need thereof, wherein the subject experiences a mean change of daytime ambulatory heart rate over a treatment period of less than about 1.25 bpm.

42. The composition of claim 41, wherein the subject experiences a mean change of daytime ambulatory heart rate over a treatment period and wherein the mean change from that of a subject taking a placebo is less than about 1.0 bpm.

43. A composition comprising about 75 mg of vibegron for use in maintaining 24-hour ambulatory blood pressure while treating overactive bladder in a subject in need thereof, wherein the subject experiences a mean change of 24-hour ambulatory blood pressure over a treatment period of less than about 2.0 mm Hg.

44. The composition of claim 43, wherein the subject experiences a mean change of 24-hour ambulatory systolic blood pressure over a treatment period and wherein the mean change from that of a subject taking a placebo is less than about 0.75 mm Hg.

45. The composition of claim 43, wherein the subject experiences a mean change of 24-hour ambulatory systolic blood pressure over a treatment period of less than about 0.75 mm Hg.

46. The composition of any one of claims to 43 to 45, wherein the subject does not experience a mean change of 24-hour ambulatory diastolic blood pressure over a treatment period greater than that of a subject taking a placebo.

47. The composition of any one of claims 43 to 46, wherein the subject experiences a mean change of 24-hour ambulatory diastolic blood pressure over a treatment period of less than 0.75 mm Hg.

48. A composition comprising about 75 mg of vibegron for use in maintaining 24-hour ambulatory heart rate while treating overactive bladder in a subject in need thereof, wherein the subject experiences a mean change of 24-hour ambulatory heart rate over a treatment period of less than about 1.0 bpm.

49. The composition of claim 48, wherein the mean change from that of a subject taking a placebo is less than about 1.0 bpm.

50. The composition of any one of claims 31 to 49, wherein the subject being administered vibegron is hypertensive.

51. The composition of any one of claims 1-50, wherein vibegron is administered once per day.

52. The composition of any one of claims 1-51, wherein vibegron is administered as a free base.

53. The composition of any one of claims 1-51, wherein vibegron is administered as a pharmaceutically acceptable salt thereof.

54. The composition of any one of claims 1-53, wherein the treatment period is selected from the group consisting of about 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52 weeks.

55. The composition of any one of claims 1-53, wherein the treatment period is selected from about 2, 4, 8, 12, and 52 weeks.

56. The composition of claim 55, wherein the treatment period is about 12 weeks.

57. The composition of claim 55, wherein the treatment period is about 52 weeks.